Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 3,200 shares, an increase of 28.0% from the November 30th total of 2,500 shares. Based on an average trading volume of 14,500 shares, the short-interest ratio is currently 0.2 days.
Adlai Nortye Price Performance
Shares of NASDAQ:ANL opened at $2.31 on Tuesday. The company’s 50-day moving average price is $2.37 and its two-hundred day moving average price is $2.67. Adlai Nortye has a one year low of $1.85 and a one year high of $17.48.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Adlai Nortye in a research report on Monday, November 11th.
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Read More
- Five stocks we like better than Adlai Nortye
- How to Calculate Return on Investment (ROI)
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- What Does a Stock Split Mean?
- Micron: Why Now Is the Time to Be Brave
- Stock Average Calculator
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
